Meldungen aus Calgary, Alberta

21.08.2018 – 21:19

General Intermediates of Canada

General Intermediates of Canada, an Alberta Biotech Company, Receives Canadian Government Funding for Immuno-Oncology Project

Edmonton, Alberta (ots/PRNewswire) - Edmonton's GIC in pursuit of new immuno-oncology therapy Edmonton's General Intermediates of Canada Inc. (GIC) announced today that they have received conditional funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) related to ...

04.10.2017 – 14:03

ARC Energy Research Institute

ARC Energy Research Institute Report: How to Invest in Crude Oil in a Carbon Constrained World

Calgary, Alberta (ots/PRNewswire) - Responding to the need for more vigilant action on mitigating carbon emissions, the ARC Energy Research Institute ('ARC') has released "Crude Oil Investing in a Carbon Constrained World: 2017 Update ...

29.08.2017 – 20:03

Resverlogix Corp.

Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial

Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that key findings from the recently completed CANTOS trial, which demonstrate that targeting residual inflammatory risk resulted in a reduction in the incidence of Major Adverse Cardiovascular ...

25.07.2017 – 15:02

Resverlogix Corp.

Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial

Calgary, Alberta (ots/PRNewswire) - "BETonMACE Phase 3 Trial with apabetalone to expand to include the United States" Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the receipt of a positive Type C written response from the Division of Metabolism and Endocrinology Products of the ...

10.07.2017 – 13:01

Resverlogix Corp.

Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial

Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the first patient has been randomized in Taiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular disease ("CVD") and type 2 ...

31.05.2017 – 13:01

Resverlogix Corp.

Resverlogix to Host Epigenetics Focused Symposium at The ERA-EDTA Congress in Madrid, Spain

Calgary, Alberta (ots/PRNewswire) - The symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress highlights BET-inhibition and apabetalone in addressing the significant unmet medical need in chronic kidney disease and cardiovascular disease. Resverlogix Corp. ...

30.05.2017 – 13:01

Resverlogix Corp.

Resverlogix Receives Approval From Health Canada to Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone

Calgary, Alberta (ots/PRNewswire) - Apabetalone expands in to first orphan disease clinical trial in patients with Fabry disease Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that it has received approval from Health Canada, Therapeutic Products Directorate, to proceed with a clinical ...

24.05.2017 – 15:31

OncoQuest Inc.

OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Edmonton, Alberta (ots/PRNewswire) - OncoQuest Inc. ("OncoQuest"), a privately held, biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced the presentation of initial safety and efficacy data from the company's ...

23.05.2017 – 13:01

Resverlogix Corp.

Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success

Calgary, Alberta (ots/PRNewswire) - Nature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today highlighted two additional works involving its lead drug, apabetalone, one recently published ...

15.05.2017 – 16:30

Resverlogix Corp.

Resverlogix Receives Approval From the FDA Cardiovascular and Renal Division to Proceed With a Requested Apabetalone Clinical Trial

Calgary, Alberta (ots/PRNewswire) - Apabetalone expands to a second major clinical indication in kidney dialysis patients Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the acceptance, by the Cardiovascular and Renal Products Division of the U.S. Food and Drug Administration ...

23.01.2017 – 13:01

Resverlogix Corp.

Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments

Calgary, Alberta (ots/PRNewswire) - Several Key Proteins That Drive Kidney (Renal) Disease and Dialysis Risk are Downregulated After a Single Dose of Apabetalone Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced preliminary results from the New Zealand based Phase 1 trial with severe ...

29.08.2016 – 17:58

Resverlogix Corp.

Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy

Calgary, Alberta (ots/PRNewswire) - The presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of high risk cardiovascular disease and diabetes. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Sunday, ...

11.08.2016 – 13:01

Resverlogix Corp.

Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board for Phase 3 Study of Apabetalone (RVX-208)

Calgary, Alberta (ots/PRNewswire) - A data review by the independent Data Safety Monitoring Board resulted in a verbal recommendation for the BETonMACE trial to continue as planned without any modification. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the independent Data and ...

21.07.2016 – 21:29

Resverlogix Corp.

Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs

Calgary, Alberta (ots/PRNewswire) - The commencement of this Phase 1 pharmacokinentic (PK) trial in patients with severe renal impairment is the first in a series of planned clinical trials designed with value creation in mind. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that dosing ...

25.05.2016 – 01:52

Resverlogix Corp.

Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)

Calgary, Alberta (ots/PRNewswire) - "Apabetalone, a selective bromodomain extra-terminal (BET) protein inhibitor that significantly decreases abundance and activity of complement proteins" Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that new data was presented at the ERA-EDTA Congress in ...

03.03.2016 – 20:43

Tsuut'ina Nation

Media Advisory - Rt. Hon. Prime Minister Justin Trudeau to Visit Tsuut'ina First Nation

Tsuut'ina, Alberta (ots/PRNewswire) - On behalf of the elders, Council and people of the Tsuut'ina First Nation, Chief Roy Whitney is pleased to announce that Prime Minister Justin Trudeau has accepted an invitation to formally meet with and be briefed on First Nations issues by the Tsuut'ina First Nation. Tsuut'ina ...

26.10.2015 – 12:01

Resverlogix Corp.

Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone

Calgary, Alberta (ots/PRNewswire) - Apabetalone will be evaluated in a Phase 3 clinical trial in high-risk coronary artery disease and type 2 diabetes mellitus patients Resverlogix Corp. (the "Corporation") today announced the commencement of a Phase 3 clinical trial called 'BETonMACE' with lead drug apabetalone (RVX-208) in high-risk patients with ...

30.07.2015 – 21:25

RS Technologies Inc.

RS and Mosdorfer Announce Distribution Agreement

Calgary, Alberta And Weiz, Austria (ots/PRNewswire) - RS Technologies Inc. ("RS") and Mosdorfer GmbH, Mosdorfer CCL Systems Ltd. and EA Elektroarmaturen (collectively "Mosdorfer") are pleased to announce a new distribution agreement whereby Mosdorfer will act as an authorized, exclusive distributor of RS's composite utility poles to utility customers in the United Kingdom, certain European countries ...

21.07.2015 – 15:13

Resverlogix Corp.

Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital

Calgary, Alberta (ots/PRNewswire) - - TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix") announced today that it has closed the previously-announced private placement with Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink") and Eastern Capital Limited ("Eastern"). Under the terms of the transaction, Hepalink subscribed for 13,270,000 units, each ...

08.07.2015 – 13:01

Resverlogix Corp.

Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink

Calgary, Alberta (ots/PRNewswire) - TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix") announced today that it has closed a license agreement and formally entered into a definitive stock purchase agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink"). The closing of the stock purchase ...

22.06.2015 – 13:31

Resverlogix Corp.

Resverlogix Officially Attains Phase 3 Status With a European Regulatory Authority

Calgary, Alberta (ots/PRNewswire) - TSX Exchange Symbol: RVX Resverlogix Corp. today announced that following recent meetings with various European regulatory bodies, the first confirmation for our Phase 3 clinical plan has officially been received. A further regulatory and protocol design update will be provided to the market post the approval of additional ...

01.06.2015 – 13:34

Resverlogix Corp.

Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)

Calgary, Alberta (ots/PRNewswire) - RVX-208, the first selective bromodomain extra-terminal (BET) protein inhibitor, significantly reduces alkaline phosphatase (ALP) levels in patients with high vascular risk Resverlogix Corp. (the "Company") today announced that new data on RVX-208 was presented at the ERA-EDTA ...

27.04.2015 – 13:01

Resverlogix Corp.

Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement

Calgary, Alberta (ots/PRNewswire) - The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million Resverlogix Corp. ("Resverlogix" or the "Company") today announced that it has entered into a Framework ...

13.04.2015 – 15:31

CGI Group Inc.

Alberta Health Extends Application Maintenance Services Contract With CGI

Edmonton, Alberta (ots/PRNewswire) - Stock Market Symbols GIB.A (TSX) GIB (NYSE) http://www.cgi.com/newsroom CGI is pleased to announce the renewal of its application maintenance services (AMS) contract with the Ministry of Health in Alberta (Alberta Health) for three years. The original contract was signed in 2011 for three and a half years, and the high ...

07.04.2015 – 13:31

Resverlogix Corp.

Resverlogix Receives Two Patents for RVX-208 in China

Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, "Compounds for the Prevention and Treatment of Cardiovascular Disease" was granted until February 2027. A manufacturing patent, China No. ZL 2009 8 0106586.7 titled, ...

24.09.2014 – 22:55

SMART Technologies Inc

SMART Technologies Files Patent Infringement Lawsuit Against CTOUCH in the Netherlands

Calgary, Alberta (ots/PRNewswire) - SMART Technologies ULC today announced the filing of a patent infringement complaint in the Netherlands before the District Court of The Hague against CTOUCH EUROPE B.V. for infringement of SMART's European Patents EP 1 739 528 and EP 1 420 335 by the CTOUCH Leddura, Leddura XT ...

23.07.2014 – 16:12

Resverlogix Corp.

RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus

Calgary, Alberta (ots/PRNewswire) - In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism. Resverlogix Corp. announced today findings from the recent analysis of Major Adverse Cardiovascular Events (MACE) data in ...

123Nächste